Accreditation Information

 

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

ICPE Credit: This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.

Medicine (ACCME)

CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This knowledge-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-19-014-L01-P)

Nursing (ANCC)
This activity is designated for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Physician Assistants (AAPA)
Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.

Needs Statement

This interprofessional, community Grand Rounds initiative is targeted to addressing the professional practice of physicians, pharmacists, nurse practitioners, physician assistants, nurses, and other healthcare professionals, who manage patients who are taking anticoagulation therapy, and who may require reversal agents for direct oral anticoagulants to address acute bleeding complications. There will be an in-depth discussion regarding assessing the risk of life-threatening bleeding in patients, understanding the novel pharmacology of specific anticoagulation reversal agents, and developing institution-specific protocols based on recent clinical evidence.

Objectives

At the conclusion of this application-based activity, participants will be able to:

  1. Identify patient groups who are at risk for experiencing emergent or life-threatening bleeding as a result of anticoagulation therapy.
  2. Assess the risk for emergent or life-threatening bleeding in patients who require anticoagulation therapy and appraise current recommendations for managing bleeding complications.
  3. Explore the novel pharmacology and clinical utility of available specific anticoagulation reversal agents.
  4. Develop treatment strategies and institution-specific protocols based on clinical evidence for recently approved anticoagulation reversal therapies to promote patient access and effective management of acute major bleeding.

Target Audience

Physicians, pharmacists, nurse practitioners, physician assistants, nurses, and other healthcare professionals who manage patients who are taking anticoagulation therapy, and who may require reversal agents for direct oral anticoagulants to address acute bleeding complications.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD - has no relevant financial relationships to disclose in relation to the content of this activity.

Gregory Piazza, MD - has disclosed that he is a consultant for Pfizer, Portola, and Thrombolex. He also receives grant/research support from Bristol-Myers Squibb, BTG/EKOS, Daiichi-Sankyo, and Janssen.

Toby C. Trujillo, PharmD, FCCP, FAHA, BCPS-AQ Cardiology - has disclosed that he is a consultant for CSL Behring, Janssen, and Portola.

Presenters:

 

 

J. Antonio T. Gutierrez MD- has no relevant financial relationships to disclose in relation to the content of this activity.

Gregory Piazza, MD - has disclosed that he is a consultant for Pfizer, Portola, and Thrombolex. He also receives grant/research support from Bristol-Myers Squibb, BTG/EKOS, Daiichi-Sankyo, and Janssen.

 

Toby C. Trujillo, PharmD, FCCP, FAHA, BCPS-AQ Cardiology - has disclosed that he is a consultant for CSL Behring, Janssen, and Portola.